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Abstract
SERPINA3K is a member of the serine proteinase inhibitor (SERPIN) family. Here we evaluated the therapeutic effects of
SERPINA3K on neovascularization and inflammation in a rat cornea alkali burn model that is commonly employed to study
corneal wounding. Topical treatment of the injured rat cornea with SERPINA3K (20 mg/eye/day) for 7 days significantly
decreased the neovascular area, compared with the groups treated with BSA or PBS. The SERPINA3K treatment also
ameliorated the corneal inflammation as evaluated by the inflammatory index. Furthermore, SERPINA3K enhanced the
recovery of corneal epithelium after the alkali injury. Toward the mechanism of action, SERPINA3K down-regulated the
expression of the pro-angiogenic and pro-inflammatory factors, vascular endothelial growth factor and tumor necrosis
factor-a and up-regulated the expression of the anti-angiogenic factor, pigment epithelium-derived factor. SERPINA3K
specifically inhibited growth of vascular endothelial cells. Meanwhile, SERPINA3K significantly up-regulated the expression
of EGFR in the corneal epithelium. These findings suggest that SERPINA3K has therapeutic potential for corneal
inflammation and NV.
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Introduction
Corneal injury is a common ophthalmologic disease and lacks
satisfactory therapies [1]. Angiogenesis or neovascularization (NV)
and inflammation are important pathologic events during the corneal
wounding and healing [2,3]. Vascular endothelial growth factor
(VEGF) and tumor necrosis factor-a (TNF-a) are known to play
important roles in the pathogenesis of NV and inflammations [4–6].
It has been shown that there are counter-balance systems which
regulate angiogenesis or NV, the pro-angiogenic factors, such as
VEGF, and the anti-angiogenic factors, such as pigment
epithelium-derived factor (PEDF) [7–10]. A major category of
the natural angiogenic inhibitor is the serine proteinase inhibitor
(SERPIN) family, as a number of serpin members (e.g. PEDF,
SERPINA3K, maspin, a1-antitrypsin, anti-thrombin) have been
identified as endogenous angiogenic inhibitors [11–15].
SERPINA3K, also known as kallikrein-binding protein (KBP),
belongs to the SERPIN family. It is expressed in the liver, kidney
and ocular tissues, etc [16–18]. SERPINA3K was first identified as
a specific inhibitor of tissue kallikrein. It specifically binds with
tissue kallikrein to form a covalent complex and inhibit its
proteolytic activities. Later studies reported that it has other
functions independent of inhibition of tissue kallikrein [19,20].
SERPINA3K has effects of anti-angiogenesis, anti-inflammation,
anti-fibrosis and anti-oxidative stress in the retina [21,22]. It was
previously reported that SERPINA3K blocks the binding of
VEGF to VEGF receptor through competing on heparin binding,
since both VEGF and SERPINA3K are heparin-binding proteins
[20]. Lately, it was suggested that SERPINA3K blocks the
canonical Wnt pathway, and consequently, down-regulates
expression of pro- inflammatory and pro-angiogenic factors such
as VEGF, TNF-a and ICAM-1, which may represent a unifying
mechanism underlying its anti-angiogenesis and anti-inflammation
effects [23]. However, little is known about potential application of
SERPINA3K in the corneal injury.
In this present study, we for the first time investigated the anti-
angiogenic and anti-inflammatory effects of SERPINA3K in the
cornea using an alkali burn model and explored its mechanism of
action.
Materials and Methods
Materials: The antibodies of VEGF, PEDF, TNF-a, epidermal
growth factor receptor (EGFR) were purchased from Abcam,
Cambridge, MA, USA. Antibody for b-actin was purchased from
Bio-Rad, Hercules, CA, USA. AlexaFluor488-conjugated IgG was
purchased from Invitrogen, Carlsbad, CA, USA. MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] was pur-
chased from Sigma, Saint Louis, MO, USA. Fluorescein sodium
solution was purchased from Jingming Co. Ltd, Tianjing, China).
Purification of SERPINA3K
The SERPINA3K/pET28 plasmid expressing SERPINA3K
was introduced into E. coli strain BL21. The vector provides a
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periplasmic space. The expression and purification followed the
protocol recommended by G.E Company with some modifica-
tions. Briefly, expression was induced by the addition of
isoprupylthio-b-galactoside (IPTG) and carried out overnight at
25uC. Periplasmic proteins were released by digestion with
lysozyme and separated from cells by centrifugation. SERPINA3K
was purified by passing through the His-Bind column (G.E). The
purity of recombinant SERPINA3K was examined by SDS-
PAGE. Endotoxin concentrations were monitored using a limulus
amebocyte kit. Activity of the purified protein was examined by
MTT assay using primary Human Umbilical Vein Endothelial
Cells (HUVEC).
Procedure of corneal alkali burn
Twenty-four male Wistar rats (150–180 g) were purchased from
Shanghai Shilaike Laboratory Animal Co, Ltd., Shanghai, China.
Animal experiments were carefully conducted in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and the animal experimental procedures were
approved by the Experimental Animal Committee of Xiamen
University (approval ID: XMUMC2009-02-1). Animals were
housed in a temperature, humidity, and light controlled room.
Food and water were available ad libitum. The procedures of
corneal alkali burn were briefly as follows: The rats were
anesthetized with an intraperitoneal injection of 40 mg/kg
pentobarbital and received topically administration with a drop
of tetracaine. A round filter paper (3.5 mm in diameter) soaked
with 1 N NaOH or PBS was placed on the center of the corneal
surface for 30 sec to induce alkali burn. The ocular surface was
then rinsed with 10 ml PBS. Rats were randomly divided into 4
groups (n=6). Group 1: Control group, without alkali burn;
Group 2: alkali burn with PBS treatment (10 ml, 4 times per day);
Group 3: alkali burn with BSA treatment (500 mg/ml in volume of
10 ml, 4 times per day) and group 4: alkali burn with SERPINA3K
treatment (500 mg/ml in volume of 10 ml, 4 times per day, daily, in
a dose of 20 mg/eye/day). All eyes were observed on day 1, 2, 5
and 8 with slit lamp microscopy as described below for evaluation
of corneal NV and inflammation and measurement of corneal
epithelium damage. The rats were sacrificed on postoperative day
8, eye balls were removed, and the corneas were dissected and
stored at 280uC for histological and immunological studies.
For the histology examination and immunofluorescent staining,
the corneas were embedded in OCT, cross-sectioned, Hematox-
ylin and Eosin staining (H&E staining) was conducted or the
immunofluorescent staining was performed as described below.
For the Western blot analysis, the whole cornea tissue including
limbal (about 0.5 mm width) area was carefully dissected and
Western blotting was conducted as described below.
Evaluation of NV and inflammation
Corneal NV (NV) was quantified as previously described with
modifications [24]. Briefly, all eyes were examined by a blinded
ophthalmologist under slit lamp microscope on day 1, 2, 5 and 8
after alkali burn. The corneal image was divided into 4 quarters.
The vessel length of each quarter (Li, i=1–4) was measured using
a vernier caliper. The corneal NV area (A) was calculated using
the following equation: A=Si=1–4 3.14166{R
22(R2Li)
2}. (R is
the radius of rat cornea. R=3.5mm, taken from the measure-
ments of 20 rat corneas).
Inflammatory response was evaluated by slit lamp. Serial
photographs of the cornea were taken. The inflammatory index
was measured as previously described [25]. Briefly, the inflam-
matory index was analyzed, based on the following parameters:
ciliary hyperemia (absent, 0; present but less than 1 mm, 1; present
between 1 and 2 mm, 2; present and more than 2 mm, 3); central
corneal edema (absent, 0; present with visible iris details, 1; present
without visible iris details, 2; present without visible pupil, 3); and
peripheral corneal edema (absent, 0; present with visible iris
details, 1; present without visible iris details, 2; present with no
visible iris, 3). The final inflammatory index result was obtained by
summing the crosses of the different parameters divided by a factor
of 9 [25].
Measurement of corneal epithelium damage
On days 1, 2, 5 and 8 after the alkali burn, all eyes were
examined by a masked ophthalmologist. The fluorescein tests were
performed as follows [26]: 5 ml 0.1% fluorescein sodium solution
was instilled in each eye of the rats. After 60s, the eyes were
examined with cobalt blue light. Pictures were taken with a digital
camera. The extent of corneal damage was scored according to the
following scale: 0, no staining; 0.5, slight punctate staining; 1,
diffuse punctate staining; 2, diffuse staining covering less than one
third of the cornea; 3, diffuse staining covering more than one-
third of the cornea; and 4, staining covering more than two-third
of the cornea.
Immunofluorescent staining
Twelve cryostat sections (6 mm in thickness) of each cornea were
fixed in acetone, blocked, and incubated with an anti-EGFR
antibody (1:400) at 4uC overnight. After further incubation in
AlexaFluor488-conjugated IgG (1:1000), sections were counter-
stained with DAPI, mounted, and photographed using a confocal
laser scanning microscope (Fluoview 1000, Olympus, Tokyo,
Japan). Negative controls without primary antibodies were
performed.
Western blot analysis
Proteins of cornea from each group were extracted with cold
PIPA buffer. Equal amounts of proteins extracted from lysates
were subjected to electrophoresis on 8% Tricine gels and then
electrophorectially transferred to PVDF membranes. After 1h
blocking in 5% BSA, the blots were incubated with primary
antibodies to VEGF (1:500), PEDF (1:200), TNF-a (1:700), EGFR
(1:5000), b-actin (1:5000) as a loading control. After three times
washes with Tris-buffered saline with 0.05% Tween 20 for 10 min
each, the membranes were incubated with HPR conjugated goat
anti-rabbit and IgG (1:10000) for 1h at room temperature. The
specific binds were visualized by enhanced chemiluminescence
reagents and recorded on film.
Cell culture
Human Corneal Epithelial (HCE) cells were obtained from
RIKEN Biosource Center (Tokyo, Japan) and were cultured in
supplemented hormonal epithelial medium (SHEM), which
comprises DMEM-F12 supplemented with 15% heat-inactivated
fetal bovine serum, bovine insulin (5 mg/ml), recombinant human
EGF (10 ng/ml) and 1% penicillin and streptomycin. For cell
viability assay, the HCE cells were plated at a density of 1610
4
cells per well in 96-well culture plates. When the HCE cells were
cultured to 70% confluency, the medium was removed and
changed in the medium in the present of SERPINA3K at
concentration of 20, 40, 80, 160, 320 nM and the medium in the
absent of SERPINA3K. The MTT assay was performed after
72 hrs.
Primary HUVEC were purchase from Cascade Biologics
Company (USA). They were cultured in medium M-200
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penicillin and streptomycin. The seeding density was between
2.5610
3 cells/cm
2 and 1610
5 cells/cm
2. The media were
changed every 3 days. When the HUVEC were cultured to 70%
confluency, the medium was removed and changed in the medium
containing SERPINA3K at concentration of 20, 40, 80, 160,
320 nM and the medium containing the same amount of BSA.
The MTT assay was performed after 72 hrs.
MTT assay
Briefly, 100 ml of 1 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5- diphenyltetrazolium bromide] constituted in culture media
was added into each well, followed by incubation for 4h at 37uCi n
the dark. After incubation, the MTT solution was removed and
the stained cells were washed twice in PBS followed by air-drying.
The MTT-formazan products were extracted with 100 mlo f
DMSO in the dark at room temperature. The absorbance was
measured sepctrophotometrically at 570 nm using a Bio Tek
ELX800 microplate reader (USA).
Statistical analysis
The statistical analysis of NV, inflammation and epithelium
damage was performed with two-way analysis of variance test
(ANOVA), followed by the Bonferroni post hoc analysis to
compare the differences between the groups. The statistical
analysis of all Western blotting results was conducted with one-
way analysis of ANOVA, followed by post hoc analysis Tukey test
to compare the differences between the groups. The data of MTT
were analyzed with student t-test. P,0.05 was considered
statistically significant.
Results
Effects of SERPINA3K on corneal NV
On day 8 after alkali burn, significant NV was observed in the
cornea treated with the PBS or BSA. The corneas treated with
SERPINA3K showed apparently less NV (Fig. 1D), compared
with the PBS or BSA-treated groups (Fig. 1B, 1C). The NV was
quantified using measurement of area of NV, which showed that
the NV area in the SERPINA3K-treated group was significantly
reduced on both days 5 and 8, compared with the PBS or BSA-
treated groups (Fig. 1E, data are presented as Mean6SEM, n=6
in each group, *** p,0.001 ), suggesting an inhibitory effect on the
corneal NV.
Anti-inflammatory effects of SERPINA3K in the cornea
The alkali burn induced apparent inflammation in the cornea,
i.e. edema and opacity of cornea (Fig. 2 A–D), on day 8 after alkali
burn. At the same time point, the cornea with SERPINA3K
treatment appeared more transparent with less edema (Fig. 2D),
compared with that in the PBS or BSA-treated groups (Fig. 2B,
2C). The measurement of inflammatory index demonstrated that
the SERPINA3K-treated group had significantly reduced inflam-
mation on days 5 and 8, compared with the PBS or BSA-treated
groups at the same time points (Fig. 2E, data are presented as
Mean6SEM, n=6 in each group, ** p,0.01; *** p,0.001).
Meanwhile, histological analysis of the corneal sections with
H&E staining showed that SERPINA3K decreased inflammatory
cell infiltration in the corneal stroma (Fig. 2G–I). The SERPI-
NA3K treatment also attenuated the alkali burn-induced thicken-
ing of the cornea, suggesting improved corneal edema (Fig. 2G–I).
The exudation attached to endothelium was also apparently
decreased in the SERPINA3K treated group, compared to the
PBS or BSA-treated groups (Fig. 2G–I).
Effects of SERPINA3K on the epithelium recovery
It was demonstrated by fluorescein sodium staining that the
corneal epithelium defect after alkali burn was smaller and the
corneal epithelium surface became smoother in the SERPINA3K-
treated group on day 8 following the alkali burn, compared to the
PBS and BSA-treated groups (Fig. 3A–D). Quantification of
epithelium defect showed a significant reduction of epithelium
damage in the SERPINA3K-treated group, compared with the
PBS or BSA-treated groups on day 8 after alkali burn (Fig. 3E,
data are presented as Mean6SEM, n=6 in each group,
** p,0.01 ).
Figure 1. Effects of SERPINA3K on corneal NV (NV). (A–D) Representative images of NV on day 8 after alkali burn. (A) control group, without
alkali burn, (B) alkali burn with PBS treatment; (C) alkali burn with BSA treatment; (D) alkali burn with SERPINA3K (SA3K) treatment (20 mg/eye/day).
The new vessels were seen in the corneas (B–D) and the new vessels were reduced in (D), compared to (B) and (C), as the arrow indicates. (E) The
statistic comparison of NV between the groups (data are presented as Mean6SEM, n=6 in each group). The area of NV was significantly reduced in
the SERPINA3K treated group on day 5 and 8, compared to PBS or BSA treated groups. (*** p,0.001).
doi:10.1371/journal.pone.0016712.g001
SERPINA3K Ameliorates Corneal Injury
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16712Figure 2. Anti-inflammatory effects of SERPINA3K in cornea. (A–D) Representative slit lamp images of the cornea on day 8 after burn. (A)
control group, without alkali burn (B) alkali burn with PBS treatment; (C) alkali burn with BSA treatment; (D) alkali burn with SERPINA3K (SA3K)
treatment (20 mg/eye/day). The edema and opacity of cornea were seen in (B) and (C) and were attenuated in (D). (E) The statistic analysis of
inflammatory index between the groups (data are presented as Mean6SEM, n=6 in each group). The inflammatory index was significantly reduced
in the SERPINA3K-treated group on days 5 and 8, compared with the PBS or BSA-treated groups. (** p,0.01; *** p,0.001) (F–I) Images of H&E
staining on day 8 after burn. (F) Control group, without alkali burn (G) alkali burn with PBS treatment; (H) alkali burn with BSA treatment; (I) alkali
burn with SERPINA3K treatment (20 mg/eye/day). The increased thickness of cornea, the increased inflammatory cells in the stroma and the
attachment of exudation to endothelium were seen in (G) and (H), and the inflammation was ameliorated in (I). Scale bar: 100 mm.
doi:10.1371/journal.pone.0016712.g002
Figure 3. Effects of SERPINA3K on the epithelium recovery. (A–D) Representative images of fluorescein sodium staining of corneal on day 8
after the alkali burn. (A) control group, without alkali burn (B) alkali burn with PBS treatment; (C) alkali burn with BSA treatment; (D) alkali burn with
SERPINA3K (SA3K) treatment (20 mg/eye/day). Stained dots were seen in the central cornea area of (B) and (C), the stained dots were significantly
reduced in (D), as arrows indicate. (E) The statistic analysis of measurement of epithelium damage between the groups (data are presented as
Mean6SEM, n=6 in each group). The epithelium damage was significantly reduced in the SERPINA3K-treated group on day 8, compared with the
PBS or BSA-treated groups. (** p,0.01).
doi:10.1371/journal.pone.0016712.g003
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by SERPINA3K
To investigate the mechanism underlying the anti-angiogenic
and anti-inflammatory effects of SERPINA3K in the cornea, we
measured pro-angiogenic and pro-inflammatory factors: VEGF
and TNF-a, and endogenous anti-angiogenic factor PEDF in the
cornea. As shown by Western blot analysis, alkali burn
significantly induced expression of VEGF and TNF-a on day 8
after alkali burn, compared to control corneas (* p,0.05;
*** p,0.001). SERPINA3K significantly down-regulated the
levels of VEGF (Fig. 4A, 4B) and TNF-a (Fig. 4D, 4E) in
the corneas with alkali burn, compared to the BSA-treated group
(* p,0.05; *** p,0.001). In the same corneas, SERPINA3K up-
regulated the level of PEDF (Fig. 4A, 4C), compared to the BSA-
treated group (data are presented as Mean6SEM, n=3 in each
group, ** p,0.01). These results suggest that SERPINA3K
restored the VEGF:PEDF balance (Fig. 4A–C), which may be
responsible for the beneficial effect on NV.
To investigate the differential effects of SERPINA3K on the
endothelial cells and epithelial cells, HUVEC and HCE cells were
employed. As shown in Figure 4F, at the concentrations of 0, 20,
40, 80, 160 and 320 nM, SERPINA3K inhibited the cell growth
of HUVEC in a concentration-dependent manner, but did not
significantly affect the cell viability of HCE cells, suggesting that
SERPINA3K has specific inhibitory effect on endothelial cells
(data are presented as Mean6SEM, n=5 in each group).
SERPINA3K regulates EGFR
To investigate the mechanism responsible for the enhanced
epithelium recovery by SERPINA3K, the expression of EGFR
was analyzed. As shown by the immunofluorescent staining, the
expression of EGFR in the layer of epithelium cells was apparently
increased in the SERPINA3K-treated group (Fig. 5D) on day 8
after the alkali burn, compared with the PBS and BSA-treated
groups (Fig. 5B, 5C). Likewise, Western blot analysis showed that
levels of EGFR were reduced by alkali burn but elevated by
SERPINA3K significantly, compared to the PBS and BSA-treated
groups (Fig. 5E, 5F, data are presented as Mean6SEM, n=3 in
each group, ** p,0.01; *** p,0.001), suggesting that the
SERPINA3K-enhanced epithelium recovery after alkali burn
may be through up-regulating EGFR.
Discussion
It has been reported that SERPINA3K has anti-angiogenic,
anti-inflammatory and anti-oxidant effects in the retina [20–22].
Figure 4. Down-regulation of anti-angiogenic and anti-inflammatory factors by SERPINA3K. (A) Western blotting results of VEGF and
PEDF on day 8 after alkali burn. Individual lanes from left to right, 1 & 2: control group, without alkali burn; 3 & 4: alkali burn with PBS treatment; 5 & 6:
alkali burn with BSA treatment; 7–8: alkali burn with SERPINA3K (SA3K) treatment (20 mg/eye/day). (B) The statistic analysis of Western blotting results
of VEGF between the groups on day 8 (Data are presented as Mean6SEM, n=3 in each group). The level of VEGF was significantly reduced in the
SERPINA3K-treated group, compared to the BSA-treated group. (C) The statistic analysis of Western blotting results of PEDF between the groups
(data are presented as Mean6SEM, n=3 in each group) on day 8. The level of PEDF was significantly up-regulated in the SERPINA3K-treated group,
compared to the BSA-treated group. (D) The Western blotting results of TNF-a on day 8 after alkali burn. The order of individual lanes was as same as
(A). (E) The statistic analysis of Western blotting results of TNF-a between the groups on day 8 (data are presented as Mean6SEM, n=3 in each
group). The level of TNF-a was significantly reduced in the SERPINA3K-treated group, compared to the BSA-treated group. (F) The effects of
SERPINA3K on the cell viability of HCE cells and HUVEC by the MTT assay (data are presented as Mean6SEM, n=5 in each group). It showed the
inhibitory effect of SERPINA3K on the cell viability of HUVEC, but not HCE cells at the concentrations given. (* p,0.05; ** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0016712.g004
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reported previously. In this present study, we provided the first
evidence that SERPINA3K ameliorates corneal NV and inflam-
mation in a corneal injury model. This study also indicated that
these beneficial effects may be mediated through down-regulation
of pro-angiogenic and pro-inflammatory factors and up-regulation
of endogenous angiogenic inhibitors. Furthermore, our results
showed that SERPINA3K also enhanced corneal epithelium
recovery after the injury, possibly via up-regulating EGFR
expression, a novel activity of SERPINA3K.
It has been established that VEGF is a key pro-angiogenic and
pro-inflammatory factor. It plays an important role in angiogenesis
and inflammation. Multiple studies suggest that blocking VEGF
expression or neutralizing its activities is an effective strategy in the
treatment of neovascular disorders [27,28]. Alkali burn signifi-
cantly up-regulated VEGF, which may contribute to corneal NV
and inflammation in this model. The over-expression of VEGF
induced by alkali burn was attenuated by SERPINA3K, which
may be responsible, at least in part, for the anti-NV effect of
SERPINA3K in the model. It has been reported that SERPI-
NA3K is an inhibitor of the Wnt pathway [23]. Since the Wnt
pathway is known to up-regulate angiogenic factors including
VEGF, it is likely that SERPINA3K may down-regulate VEGF
via blocking the Wnt pathway.
PEDF is a potent endogenous inhibitor of angiogenesis and
inflammation [8,9]. It contunter-balances the activity of VEGF
and plays an important role in angiogenesis control. The disturbed
balance between VEGF and PEDF has been implicated in NV.
Here we showed for the first time that SERPINA3K up-regulates
endogenous PEDF expression, which may be another mechanism
for its anti-inflammatory and anti-angiogenic effects.
SERPINA3K and PEDF are both members of the SERPIN
family, and share significant sequence homology [18]. In this
study, the increased VEGF level and the decreased level of PEDF
was observed after the cornea was chemically injured with alkali.
The treatment of SERPINA3K significantly attenuated the VEGF
over-expression induced by the alkali burn while significantly
elevated the PEDF levels. These results suggest that SERPINA3K
mediates angiogenesis and inflammation likely via regulating the
VEGF:PEDF balance, i.e. down-regulating VEGF and up-
regulating PEDF expressioin.
Vascular endothelial cells are widely used to study the
mechanism for NV [34,35]. It has been well documented that
primary HUVEC can be activated by VEGF and thus is employed
as an in vitro model for anti-VEGF therapy or other anti-NV
strategies [34,35]. In the present study, we used HUVEC to
compare the specific inhibition of SERPINA3K on the vascular
endothelial cells. We demonstrated that SERPINA3K has specific
inhibitory effects on the cell growth of HUVEC, but not HCE
cells. Since we have found recently that SERPINA3K is an
antagonist of the canonical Wnt pathway which regulates multiple
angiogenic factors including VEGF and TNF-a [23]. This may
represent a mechanism responsible for its inhibitory effect on
endothelial cell growth. However, the mechanism by which
SERPINA3K regulates EGFR remains to be studied in the future.
Tumor necrosis factor-a (TNF-a) is a commonly accepted key
inflammatory factor [29–31]. The level of TNF-a was increased
after alkali burn, which contribute to corneal inflammation.
Figure 5. SERPINA3K regulates expression of EGFR. (A–D) Representative images of the immunofluorecent staining on day 8 after burn. (A)
control group, without alkali burn (B) alkali burn with PBS treatment; (C) alkali burn with BSA treatment; (D) alkali burn with SERPINA3K (SA3K)
treatment (20 mg/eye/day). It was shown that the expression of EGFR in the layer of epithelium cells of SERPINA3K (SA3K) treated group was
apparently increased on day 8 (D), compared to the PBS and BSA-treated groups (B, C). (E) Western blotting results of EGFR on day 8 after alkali burn.
Individual lanes from left to right, 1 & 2: control group, without alkali burn; 3 & 4: alkali burn with PBS treatment; 5 & 6: alkali burn with BSA treatment;
7 & 8: alkali burn with SERPINA3K treatment (20 mg/eye/day). (F) The statistic analysis of Western blotting results of EGFR between the groups on day
8 after alkali burn (data are presented as Mean6SEM, n=3 in each group). The level of EGFR was significantly up-regulated in the SERPINA3K-treated
group, compared to that in the BSA-treated group (** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0016712.g005
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alkali burn, correlating with other beneficial effects on the
pathologic changes caused by the burn, e.g. the decrease of
inflammation index (Fig. 2E) and decrease of inflammatory cells in
the stroma (Fig. 2I), suggesting that SERPINA3K’s inhibitory
effect on the inflammation of injured cornea can be at least
partially ascribed to the down-regulation of TNF-a.
In contrast to its inhibitory effect on NV, our study for the first
time showed that SERPINA3K enhances the recovery of
epithelium after injury. EGFR is the cell-surface membrane
receptor of the EGF and plays a key role in the epithelial cell
proliferation and survival [32,33]. Both our immunofluorescent
staining and Western blotting analyses showed that SERPINA3K
up-regulated the expression of EGFR in the cornea. The up-
regulation of the expression of EGFR by SERPINA3K under
pathological conditions may represent a mechanism responsible
for the enhancing effect of SERPINA3K on epithelium recovery.
Corneal wounding is a common eye disease worldwide,
particularly in the developing countries. Corneal wounding
involves a very complicated battery of pathologic alterations,
including NV, inflammation and epithelium recovery etc. The
present study proved again that multiple factors, such as VEGF,
PEDF, TNF-a are involved in the corneal wounding. We provided
novel evidence of the new direction and hint for the treatment of
corneal wounding, and SERPINA3K can become a potential
therapeutic agent for the corneal wounding.
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